Apixaban

Q: What is Apixaban used for?

Apixaban is evaluated for the following indications with varying evidence strength: Venous thromboembolism (evidence tier A), Non-valvular atrial fibrillation (evidence tier A), Mechanical heart valve (evidence tier F). See the full indication matrix with dosing and citations above on this page.

Q: What are the side effects of Apixaban?

Common side effects of Apixaban (≥ 1 in 100): Epistaxis, gum bleeding, Hematuria, occult fecal blood, Bruising, petechiae, Anemia (chronic loss), Nausea. See the Safety section for uncommon and serious reactions.

Q: Is Apixaban safe during pregnancy?

FDA category B. FDA pregnancy categories were retired in 2015 (historically category B). Pregnancy data are limited. Apixaban crosses the placenta. In pregnant patients requiring anticoagulation, low-molecular-weight heparins (enoxaparin, dalteparin) are standard — not DOACs.

Q: Is Apixaban compatible with breastfeeding?

Data are limited. The manufacturer and most international sources recommend avoidance. Switch to LMWH or warfarin if anticoagulation is needed during breastfeeding.

Q: Who should not take Apixaban?

Apixaban is contraindicated in: Active clinically significant bleeding; Lesion or condition at high risk of major bleeding; Concomitant treatment with another anticoagulant (except bridging regimens); Hepatic disease with coagulopathy and clinically relevant bleeding risk; Mechanical heart valves. Full list in the Safety section.

Q: Does Apixaban carry an FDA boxed warning?

FDA boxed warning: premature discontinuation of apixaban increases the risk of thrombotic events, including stroke in atrial fibrillation. Any interruption requires a clear plan to bridge with an alternative anticoagulant.

Q: long-term DOAC use destroys the liver

apixaban hepatotoxicity is rare and routine ALT/AST monitoring is not required. Duration is dictated by the indication (often lifelong in high-risk AF).

Q: warfarin is more reliable because INR is controlled

'controllability' is not an advantage. DOACs have shown fewer hemorrhagic strokes and lower mortality than warfarin. Warfarin remains the choice in mechanical valves, rheumatic AF, and high-risk antiphospholipid syndrome.

Q: no antidote for DOAC bleeding

andexanet alfa and 4F-PCC are available and used in life-threatening bleeding.

AEMPS

Direct oral anticoagulants (factor Xa inhibitors)

ATC code: B01AF02 (Apixaban)

Brand names

Eliquis

Mechanism of action

Selective reversible direct inhibitor of activated factor Xa, blocking the conversion of prothrombin to thrombin. Does not require routine laboratory monitoring. Metabolized by CYP3A4 and is a P-glycoprotein substrate – strong CYP3A4/P-gp inhibitors and inducers are clinically relevant. Renal elimination 27 %, biliary 73 %; dose reduction is indicated for eGFR below 30 mL/min and/or body weight under 60 kg with age over 80 years.

Indications

Non-valvular atrial fibrillation

First line

First-line for stroke prevention in non-valvular atrial fibrillation per 2024 and / 2023. DOACs are preferred over warfarin in most patients. The ARISTOTLE trial (over 18,000 patients) demonstrated a 21 % reduction in stroke or systemic embolism, a 31 % reduction in major bleeding, and an 11 % reduction in all-cause mortality versus warfarin. Standard dose 5 mg twice daily. The 2.5 mg twice-daily dose applies to patients with at least two of: age ≥ 80, body weight ≤ 60 kg, or serum creatinine ≥ 133 µmol/L.

Standard dose 5 mg twice daily. Reduce to 2.5 mg twice daily if any two of three criteria are met: age ≥ 80 years, body weight ≤ 60 kg, serum creatinine ≥ 1.5 mg/dL. Clinical data are limited at eGFR < 15 mL/min/1.73 m².

Sources

ICD-10: I48.9 · ICD-11: BC81.3

Venous thromboembolism

First line

First-line treatment for deep vein thrombosis and pulmonary embolism in outpatients without contraindications per CHEST 2021 and 2019. Loading dose 10 mg twice daily for 7 days, then 5 mg twice daily for up to 6 months. For long-term secondary prevention beyond 6 months, 2.5 mg twice daily is acceptable. DOACs are not used in high-risk antiphospholipid syndrome (triple positivity) – warfarin remains standard there.

Sources

ICD-10: I82 · ICD-11: BD71

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Common cold

Not recommended

After the COVID-19 pandemic some patients took up the habit of taking apixaban, rivaroxaban, and other DOACs at the first symptoms of an upper respiratory infection «for blood thinning and thrombosis prevention». International guidelines do not support this. Outpatient viral URI is self-limiting, clinically meaningful thromboembolism risk is not elevated, and major bleeding risk on apixaban remains the same. , , ASH, and ISTH do not mention anticoagulants for outpatient URI. Evidence-based management is rest, hydration, symptomatic measures; antivirals (oseltamivir, nirmatrelvir/ritonavir) are reserved for confirmed influenza or COVID-19 in high-risk patients.

Sources

ICD-10: J00 · ICD-11: CA00

COVID-19

Not recommended

For mild and moderate outpatient COVID-19, apixaban is not prescribed for thrombosis prophylaxis. Apixaban itself was tested in the ACTIV-4B RCT (Connors et al., JAMA 2021): 657 symptomatic outpatients were randomised to aspirin 81 mg, prophylactic apixaban 2.5 mg twice daily, therapeutic apixaban 5 mg twice daily, or placebo. The trial was stopped early for futility at very low event rates: anticoagulants did not reduce hospitalisations, thromboses, or mortality, while therapeutic-dose apixaban produced a 6.9 % absolute increase in bleeding events compared with placebo. The updated ASH 2024 living guideline (Blood Advances) issued a conditional recommendation against routine post-discharge thromboprophylaxis in COVID-19; the Therapeutics Living Guideline and NG191 do not support routine DOAC use in outpatients. Non-severe hospitalised patients benefit from low-molecular-weight heparin under supervision, not oral DOACs. Self-administered Eliquis «just in case» for COVID-19 has no evidence base.

Sources

ICD-10: U07.1 · ICD-11: RA01.0

Mechanical heart valve

Not recommended

Direct oral anticoagulants are contraindicated in patients with mechanical heart valves. The RE-ALIGN trial with dabigatran was stopped early due to increased valve thrombosis and bleeding compared with warfarin. No analogous RCT exists for apixaban, and the class effect is extrapolated. In these patients, warfarin remains first-line with INR target 2.5–3.5 depending on valve position and generation.

Sources

ICD-10: Z95.2 · ICD-11: QB50.21

Practical notes

Timing and administration

Take twice daily with or without food, ideally at the same times each day. For a missed dose, take it when remembered if more than 6 hours remain before the next dose; otherwise skip and do not double up. The tablet may be crushed and mixed with water or applesauce — useful for patients on tube feeding.

Monitoring

INR monitoring is not required. At baseline and yearly (more often with comorbidities): creatinine and eGFR, liver function tests, complete blood count. In patients with eGFR 15–29 mL/min/1.73 m², check every 3–6 months. Apixaban is not used at eGFR below 15 per the European label; the US label permits 5 mg twice daily with caution.

Special situations

Before elective surgery with low bleeding risk, stop apixaban 24 hours in advance; with high bleeding risk, 48 hours. Resume after stable hemostasis, typically 24–48 hours postoperatively. Specific reversal agent: andexanet alfa (registered in the US and EU; limited availability in Russia). For life-threatening bleeding when andexanet is unavailable, use 4-factor prothrombin complex concentrate 25–50 IU/kg.

Common myths

Myth: 'long-term DOAC use destroys the liver'. Fact: apixaban hepatotoxicity is rare and routine ALT/AST monitoring is not required. Duration is dictated by the indication (often lifelong in high-risk AF).

Myth: 'warfarin is more reliable because INR is controlled'. Fact: 'controllability' is not an advantage. DOACs have shown fewer hemorrhagic strokes and lower mortality than warfarin. Warfarin remains the choice in mechanical valves, rheumatic AF, and high-risk antiphospholipid syndrome.

Myth: 'no antidote for DOAC bleeding'. Fact: andexanet alfa and 4F-PCC are available and used in life-threatening bleeding.

Drug–drug interactions

36 pairs found. Sorted from critical to minor.

Critical

Carbamazepine

Antiepileptics. Carboxamide derivatives

Mechanism

Carbamazepine is a strong CYP3A4 and P-glycoprotein inducer. Apixaban plasma concentration falls by 50–75%, eliminating stroke protection in atrial fibrillation and VTE recurrence protection. recommends avoiding the combination.

Symptoms

No overdose symptoms – the danger is undertreatment: ischemic stroke, recurrent DVT or PE despite ongoing anticoagulant.

Management

Combination contraindicated. Alternative anticoagulant when carbamazepine is needed: warfarin (effect tracked by INR, induction can be compensated). Alternative anticonvulsant: levetiracetam or lacosamide, neither induces CYP3A4.

Sources

Mechanism of action

Indications

Non-valvular atrial fibrillation

Venous thromboembolism

Common cold

COVID-19

Mechanical heart valve

Practical notes

Timing and administration

Monitoring

Special situations

Common myths

Drug–drug interactions

Check interaction with another drug

Official sources

Safety

Contraindications

Serious adverse effects

Common adverse effects

PregnancyFDA B

Frequently asked

Mechanism of action

Indications

Non-valvular atrial fibrillation

Venous thromboembolism

Common cold

COVID-19

Mechanical heart valve

Practical notes

Timing and administration

Monitoring

Special situations

Common myths

Drug–drug interactions

Check interaction with another drug

Official sources

Safety

Contraindications

Serious adverse effects

Common adverse effects

PregnancyFDA B

Frequently asked